<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871687</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000094</org_study_id>
    <nct_id>NCT02871687</nct_id>
  </id_info>
  <brief_title>Effect of Statin Use on Aldosterone Secretion</brief_title>
  <official_title>Effect of Statin Use on Aldosterone Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research protocol is to determine if the same effects are observed in
      vivo in humans through a randomized controlled study. Data regarding a novel mechanism of the
      widely used statin class of medications on the mineralocorticoid pathway would likely have
      significant clinical implications on the future management of hypertension and other
      cardiovascular disease given the known pleiotropy of aldosterone action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to provide additional evidence regarding the effect of statin therapy on aldosterone
      levels, the investigators propose the following randomized, double-blinded, placebo
      controlled protocol in relatively healthy volunteers. The investigators will evaluate
      aldosterone and cortisol production in response to an angiotensin II infusion under the
      following test conditions: 1) placebo, 2) simvastatin therapy (lipophilic statin), and 3)
      pravastatin therapy (hydrophilic statin). Measurements will be made to assess the effect of
      both acute (single dose) and chronic (3 months) therapy of the two statin medications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum aldosterone following angiotensin II infusion</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour urine aldosterone</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine aldosterone</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the simvastatin arm will receive simvastatin 40 mg daily for the 3 month duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the pravastatin arm will receive pravastatin 80 mg daily for the 3 month duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 40 mg daily</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Pravastatin 80 mg daily</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood pressure &lt;140/90 mmHg and &gt;100/50 mmHg

          -  Body mass index 27-40 kg/m2

          -  Normal screening laboratory values for:

             i. Serum sodium, potassium, glucose, liver enzymes ii. GFR (&gt;60 mL/min/1.73m2) iii.
             A1c iv. TSH

          -  Normal ECG

          -  Negative urine HCG at screening for women who are able to become pregnant.

        Exclusion Criteria:

          -  Any prior use of statin therapy

          -  History of coronary disease, diabetes, hypertension, stroke, kidney disease, thyroid
             disease, psychiatric illness, malignancy, preeclampsia, or illness requiring overnight
             hospitalization in the past 6 months

          -  Triglycerides &gt; 500, LDL &gt; 200

          -  Any prescription medication or herbal medication including oral contraceptive

          -  Pregnancy or current breastfeeding

          -  Alcohol intake &gt;12 oz per week

          -  Tobacco or recreational drug use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cara Ludwick</last_name>
    <phone>617-278-0305</phone>
    <email>cludwick1@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tina Gupta, MD</last_name>
    <phone>617-732-5666</phone>
    <email>tgupta2@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital- 221 Longwood Avenue</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baudrand R, Pojoga LH, Vaidya A, Garza AE, VÃ¶hringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation. 2015 Nov 10;132(19):1825-33. doi: 10.1161/CIRCULATIONAHA.115.016759. Epub 2015 Oct 2.</citation>
    <PMID>26432671</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gordon H. Williams, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

